Tag: weight loss

1. In this meta-analysis, the impact of interactive social media interventions aimed at increasing physical activity was evaluated. 2. Improvements were seen in daily steps taken, marginal weight loss, reducing heart rate, and overall well-being. Evidence Rating Level: 2 (Good) Social media use has increased substantially since the introduction of programs...
Use of accelerometer/pedometer-only and commercial health wearable-only were the most effective at reducing body weight in comparison with the other groups. Multicomponent accelerometer/pedometer and commercial health wearable-only interventions were the most effective at reducing body mass index in comparison to the other groups. Evidence Rating Level: 1...
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec at 52 weeks post-randomization. 2. Tirzepatide (5, 10, or 15 mg) was superior to insulin degludec for the bodyweight reductions at 52 weeks post-randomization. Evidence Rating Level: 1 (Excellent) Study Rundown: Current...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients on semaglutide 2.4 mg achieved a target HbA1c of 6.5% or less.  Evidence Rating Level: 1 (Excellent) Study Rundown: There is strong overlap between weight gain and type 2 diabetes, with the majority of diabetic patients...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients on semaglutide 2.4 mg achieved a target HbA1c of 6.5% or less.  Evidence Rating Level: 1 (Excellent) Study Rundown: There is strong overlap between weight gain and type 2 diabetes, with the...
1. The combination of liraglutide and lifestyle therapy was shown to significantly reduce body mass index (BMI) standard-deviation score compared to the placebo group. 2. The use of liraglutide as adjuvant therapy was shown to cause a higher frequency of gastrointestinal adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is a chronic...
1. The combination of liraglutide and lifestyle therapy was shown to significantly reduce body mass index (BMI) standard-deviation score compared to the placebo group. 2. The use of liraglutide as adjuvant therapy was shown to cause a higher frequency of gastrointestinal adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Obesity is...
1. Maintaining obesity across adulthood, gaining weight from young to middle adulthood, and losing weight from middle to late adulthood, are all associated with an increased risk of all-cause mortality among community-dwelling adults. Evidence Rating Level: 2 (Good) While it is known that high body mass index (BMI) is associated with...